Bacterial Pneumonia Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia
BOSTON, April 03, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today positive top-line results from a global, pivotal Phase 3 clinical study comparing its once-daily oral and IV, broad spectrum investigational... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 3, 2017 Category: Pharmaceuticals Source Type: clinical trials
A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
Conditions: Hospital-Acquired Bacterial Pneumonia; Ventilator-Associated Bacterial Pneumonia; Hospital-Acquired Pneumonia; Ventilator-Associated Pneumonia Interventions: Drug: Meropenem-Vaborbactam; Drug: Piperacillin/Tazobactam Sponsor: The Medicines Company Not yet recruiting - verified December 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2016 Category: Research Source Type: clinical trials
